Top Story

Sight Sciences receives IDE approval to initiate clinical trial of ab interno canaloplasty system vs. SLT

July 27, 2016

Sight Sciences received full investigational device exemption approval from the FDA to initiate a clinical trial comparing ab interno canaloplasty and selective laser trabeculoplasty, according to a press release.

The multicenter, prospective, randomized, controlled clinical trial will evaluate the safety and efficacy of the Visco360 viscosurgical system in reducing IOP in patients with primary open-angle glaucoma vs. SLT.

Zeiss appoints Jim Mazzo as global president of ophthalmology

July 27, 2016
Carl Zeiss Meditec appointed James V. Mazzo as global president of ophthalmology, according to a company press release. In this role, Mazzo will be responsible for…

TANZANITE study: No re-treatments required with triamcinolone acetonide formulation after 3 months

July 27, 2016
A majority of patients treated with a proprietary form of triamcinolone acetonide in combination with aflibercept required no additional treatments over 3 months…
In the Journals

Eyes with severe ocular surface disease at risk for KPro-related melt complications

July 26, 2016
Patients with severe ocular surface disease who underwent implantation of a Boston type 1 keratoprosthesis had a greater risk of developing corneal melts, leaks and…
CommentaryFrom OSN Europe

Innovative approaches may reduce carbon footprint and environmental impact of surgery

Ocular Surgery News Europe Edition, July 2016
Richard B. Packard, MD, FRCS, FRCOphth
In the cover story on the high carbon footprint of cataract surgery as performed in the developed world, we are made aware of a growing problem for the planet. It…
More News Headlines »
Clinical Science

Pars Plana Vitrectomy With in Vivo Cyst Lysis for Intraocular Cysticercosis

Ophthalmic Surgery, Lasers and Imaging Retina, July 2016, Volume 47 Issue 7
To evaluate efficacy and safety of pars plana vitrectomy (PPV) and in vivo cyst lysis for intraocular cysticercosis…
More »

Imaging Modalities in Clinical Trials

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Highlights from ASCRS

Highlights from ASCRS

Meeting News Coverage

VIDEO: Speaker talks use of spot vision screener on patients with developmental disability

July 18, 2016
More »